BIOLIGHT(SZ:300246) Xin Lang Cai Jing·2025-11-18 02:10Core Viewpoint - Baolait's stock price has shown a mixed performance this year, with a year-to-date increase of 36.72%, but a recent decline in trading activity and a net outflow of funds indicates potential investor concerns [2][1]. Company Overview - Baolait Medical Technology Co., Ltd. is located in Zhuhai, Guangdong Province, established on June 28, 1993, and listed on July 19, 2011. The company specializes in the research, production, sales, and service of medical device products [2]. - The main revenue composition includes hemodialysis products (77.51%), monitoring equipment (21.39%), and other products (1.10%) [2]. Financial Performance - For the period from January to September 2025, Baolait reported operating revenue of 793 million yuan, a year-on-year decrease of 1.77%. The net profit attributable to shareholders was -8.34 million yuan, showing a year-on-year increase of 38.85% [2]. - Cumulative cash dividends since the A-share listing amount to 244 million yuan, with 35.16 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, Baolait had 21,200 shareholders, an increase of 15.06% from the previous period. The average circulating shares per person decreased by 13.10% to 9,974 shares [2]. - Among the top ten circulating shareholders, CITIC Prudential Multi-Strategy Mixed Fund (165531) is the ninth largest with 1.055 million shares, marking its entry as a new shareholder [3].